Dear Graeme

Many thanks for your e-mail. We are doing fine with a few COVID19 cases reported daily. Social distancing and other restrictive measures with intensive testing helped us to avoid rapid escalation of the epidemic.

I am so sorry to hear that reports did not reach you since September 2019. I’ve attached e-mails sent in September-December 2019.

We missed to send to you Q1 reports. I will be sending them within the next couple of days. January 2020 report is attached.

As of the number of bottle in the stock, we have 9856 bottles of myhepall in the central stock (As of May 6 2020).

With kind regards

Tamar

პატივისცემით,

თამარ გაბუნია

მინისტრის პირველი მოადგილე

Sincerely,

Tamar Gabunia, MD, MPH

First Deputy Minister

Dear Tamar,

I hope all well with you

Thank you for the information below. I have two further questions:

1. How many bottles do you have in stock today (Inventory)
2. We used to receive a monthly report at the end of every month but have not received since September last year, would it be possible to start receiving these again?

Thank you for your help in this matter.

Best wishes

Graeme

Dear Graeme

Many thanks for your e-mail. Just a brief update on where do we stand with the program implementation for the moment- From the beginning of the HCV program implementation, including March 2020, more then 68 000 HCV patients have already started treatment and more than 62 000 completed treatment.

At this stage, we have patients on treatment regimens, with MyHeppAll.

The monthly registration in the program in January and February was around 1800 patient. In March, due to the pandemic of the corona virus and isolation activities, patient inflow was about 400 patient. It should be noted that over the ten days of April, the number of registered beneficiaries is 400, so about 800 patients are expected in April. We think we will maintain the current (800 patient per month) enrolment on MyHeppAll in the lockdown months (April, May) and after that It is expected that the flow will increase to 1200 patient per month, by the end of 2020, however, From January 2021, we plan to increase enrolment to 1500 patient per month. With this picture of the inflow, the required amount of MyHeppAll  for 2021 year (+ 3 month buffer) is about 59 000 bottles. It would be good, if we could get these in two shipment (30 000 bottles by the end of March 2021 and 29 000 bottles by the end of July 2021)

If our request is acceptable, we will provide an official order for 59 000 MyHeppAll bottles.

Regarding the last request, about the remaining 35 000 bottles for 2020, due to the pandemic of the corona virus and some flight restrictions, it would be good, if we could get all the bottles in one shipment, by the end of July 2020.

Should you have additional questions or require clarifications please kindly let me know.

პატივისცემით,

თამარ გაბუნია

მინისტრის პირველი მოადგილე

Sincerely,

Tamar Gabunia, MD, MPH

First Deputy Minister

Dear Tamar,

Thank you for this information it is very useful. Please can you kindly let me know which month you will require the remaining 35 000 bottles and if you would like these in one shipment or broken into two?

Also do you have a thought about the volumes for 2021 so we can also start planning and the months you would like delivery.

Thank you and I hope you are all keeping well and Georgia is coping with the current situation.

Best wishes

Graeme

Dear Graeme

With this I am sharing the forecast for 2020 prepared by the treatment committee.

I would like to provide you with updated information on HCV Program implementation and adjusted plan on treatment.

From the beginning of the HCV program implementation, more then 66 000 HCV patients have already started treatment and more than 61 000 completed treatment.

At this stage, we have patients on treatment regimens, with MyHeppAll.

The monthly registration in the program in January and February was around 1800 patient. In March, due to the pandemic of the corona virus and isolation activities, patient inflow was about 400 patient. It should be noted that over the ten days of April, the number of registered beneficiaries is 400, so about 800 patients are expected in April. We think we will maintain the current (800 patient per month) enrolment on MyHeppAll in the lockdown months (April, May) and after that It is expected that the flow will increase to 1200 patient per month. With this picture of the inflow, the required amount of MyHeppAll  for current and new patients (which will be included in the program by the end of 2020+ 3 month buffer), besides arrived 24 003 bottles,  is about 35 000 bottles.

Should you have any questions please kindly let me know.

პატივისცემით,

თამარ გაბუნია

მინისტრის მოადგილე

Sincerely,

Tamar Gabunia, MD, MPH

Deputy Minister

Thank you Tamar. I am glad the shipment arrived safely

Best wishes

Graeme

Dear Graeme

Many thanks for your follow up. I apologize for delayed response on your enquiries regarding the forecast. I am waiting the treatment committee’s review and response on this. We’ll check tomorrow morning and get back to you immediately.

We did receive the latest shipment from Mylan. All went well.

With kind regards

პატივისცემით,

თამარ გაბუნია

მინისტრის პირველი მოადგილე

Sincerely,

Tamar Gabunia, MD, MPH

First Deputy Minister

Dear Tamar,

I hope all well with you and you are staying safe and well during these difficult days.

I would like to follow up from our conversation last week. Please could you kindly send at your earliest convenience the forecast for sof/vel demand for the remainder of 2020 by month. I need this to instruct Mylan in time for the next set of shipments and my finance colleagues need to factor this into our budget.

Also did you receive the latest shipment from Mylan? Everything OK?

Thank you for your follow up.

Best wishes

Graeme

Many thanks!

Dear Minister Gabunia,

Nice to connect with you again. Hope you are safe and doing good.

Please find attached the shipping documents pertaining to the balance 14,667 bottles for SOF/VELPA which we plan to send by a flight which we are able to confirm as per details below:

FLIGHT DETAILS

TK 6237                 31.03.2020           BOM-ISL

TK 6374                 02.04.2020           ISL-TBS

Please let me know in case of any clarifications or concerns.

Thanks,
Dhruv

DISCLAIMER If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and may be unlawful. If your e-mail contains any personal information then we will process this according to our Privacy Statement located on Gilead.com. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. Gilead Sciences Europe Ltd ; Registered as a limited company in England and Wales ; Registered number 5510315 Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ; England

DISCLAIMER If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and may be unlawful. If your e-mail contains any personal information then we will process this according to our Privacy Statement located on Gilead.com. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. Gilead Sciences Europe Ltd ; Registered as a limited company in England and Wales ; Registered number 5510315 Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ; England

DISCLAIMER If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and may be unlawful. If your e-mail contains any personal information then we will process this according to our Privacy Statement located on Gilead.com. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. Gilead Sciences Europe Ltd ; Registered as a limited company in England and Wales ; Registered number 5510315 Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ; England

DISCLAIMER If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and may be unlawful. If your e-mail contains any personal information then we will process this according to our Privacy Statement located on Gilead.com. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. Gilead Sciences Europe Ltd ; Registered as a limited company in England and Wales ; Registered number 5510315 Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ; England